United Therapeutics (UTHR) Raised to Buy at Zacks Investment Research
United Therapeutics (NASDAQ:UTHR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Monday. The firm currently has a $160.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s price target suggests a potential upside of 14.71% from the company’s current price.
According to Zacks, “United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. The company, at present, has many phase III programs in the fields of cardiopulmonary diseases and oncology. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Several data read-outs and regulatory updates are expected in 2018. However, increased competitive pressure from Uptravi on its PAH drugs, mainly Orenitram, is a concern. We believe the company needs to use cash suitably to deal with generic competition for Remodulin that could materialize post Jun 2018. However, United Therapeutics’ shares have outperformed the industry in the past six months. Estimates have gone up ahead of the Q4 earnings release. The company has a mixed record of earnings surprises in the recent quarters. “
Several other research firms have also weighed in on UTHR. Wedbush reiterated an “outperform” rating and set a $232.00 target price (up from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. ValuEngine upgraded United Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 26th. Oppenheimer lifted their target price on United Therapeutics to $180.00 and gave the stock an “outperform” rating in a report on Friday, January 5th. TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. Finally, BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, December 6th. Four analysts have rated the stock with a sell rating, six have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $140.45.
Shares of United Therapeutics (NASDAQ UTHR) traded up $4.36 during trading on Monday, hitting $139.48. The company had a trading volume of 74,577 shares, compared to its average volume of 399,880. United Therapeutics has a twelve month low of $112.01 and a twelve month high of $169.89. The firm has a market capitalization of $6,104.42, a PE ratio of 12.30 and a beta of 1.41.
United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The business had revenue of $445.50 million during the quarter, compared to analysts’ expectations of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The firm’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the previous year, the firm earned $4.23 earnings per share. equities analysts predict that United Therapeutics will post 12.96 EPS for the current year.
In other news, Director Christopher Causey sold 580 shares of the business’s stock in a transaction dated Monday, November 6th. The stock was sold at an average price of $122.00, for a total value of $70,760.00. Following the sale, the director now directly owns 2,135 shares in the company, valued at $260,470. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 1,241 shares of the business’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $128.95, for a total value of $160,026.95. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,773 shares of company stock worth $1,925,637. Corporate insiders own 7.80% of the company’s stock.
Several institutional investors have recently modified their holdings of the company. First Allied Advisory Services Inc. lifted its holdings in shares of United Therapeutics by 0.4% in the second quarter. First Allied Advisory Services Inc. now owns 4,579 shares of the biotechnology company’s stock valued at $598,000 after purchasing an additional 19 shares in the last quarter. Fort L.P. lifted its holdings in shares of United Therapeutics by 5.2% in the second quarter. Fort L.P. now owns 2,014 shares of the biotechnology company’s stock valued at $261,000 after purchasing an additional 99 shares in the last quarter. Guardian Capital LP lifted its holdings in shares of United Therapeutics by 5.9% in the second quarter. Guardian Capital LP now owns 2,623 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 145 shares in the last quarter. M&T Bank Corp lifted its holdings in shares of United Therapeutics by 8.8% in the second quarter. M&T Bank Corp now owns 2,217 shares of the biotechnology company’s stock valued at $288,000 after purchasing an additional 179 shares in the last quarter. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of United Therapeutics by 8.6% in the second quarter. PNC Financial Services Group Inc. now owns 2,272 shares of the biotechnology company’s stock valued at $296,000 after purchasing an additional 180 shares in the last quarter.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.